Pharma: Clinic Roundup

• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said results from the pivotal Phase III GEMINI trial showed that, after six weeks of induction therapy, 47. 1 percent of patients with moderately to severely active ulcerative colitis who received gut-selective monoclonal antibody vedolizumab experienced clinical response vs. 25.5 percent in the placebo group (p < 0.0001).